Mr. Koven has served as President and Chief Business Officer at Aralez Pharmaceuticals Inc. since 2016 and held the same position in 2015 at POZEN Inc., where he was instrumental in negotiating a merger with Tribute Pharmaceuticals Canada Inc. to create Aralez Pharmaceuticals. Prior to joining POZEN, Mr. Koven was Chief Administrative Officer, General Counsel and Corporate Secretary at Auxilium Pharmaceuticals Inc., where he was responsible for legal functions, government affairs and technical operations until it was sold to Endo Pharmaceuticals in 2015. Prior to that , he held roles as Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals Inc., where he oversaw all matters related to legal, quality and compliance, corporate development and licensing and technical operations until it was acquired by Merck in 2011. From 2007-2010, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc., where he was responsible for the company’s legal and government affairs departments and Corporate Secretarial function until its sale to Dainippon Sumitomo. He served as Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals Inc. from 2003-2007 until the company was acquired by Abbott Laboratories. Before joining Kos Pharmaceuticals, he was Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003 and Assistant General Counsel at Warner-Lambert Company from 1993 to 2000. Mr. Koven holds a Master of Law Degree from Columbia University School of Law and an LL.B. Degree and Bachelor of Arts Degree in Political Science from Dalhousie University.